Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NT-112 · 1 trial · 6 indications
Incidence of DLTs, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence of DLTs, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence of DLTs, treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| NT-112 | EXPERIMENTAL | Part A Dose Escalation and Part B Dose Expansion of NT-112 |
| AZD0240 | EXPERIMENTAL | Part A Dose Escalation and Part B Dose Expansion of AZD0240 |
| Name | Type | Description |
|---|---|---|
| NT-112: Autologous, engineered T Cells targeting KRAS G12D | BIOLOGICAL | NT-112 targets KRAS G12D in the context of HLA-C\*08:02 |
| AZD0240: Autologous, engineered T Cells targeting KRAS G12D | BIOLOGICAL | AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02 |
Key Inclusion Criteria: * Age ≥18 years * Diagnosed with NSCLC, Colorectal adenocarcinoma, Pancreatic adenocarcinoma, Endometrial Cancer or any other solid tumor * Tumors must harbor a KRAS G12D variant mutation and subject must be HLA-C\*08:02 positive, HLA-A\*11:01 or HLA-A\*11:02 positive in at ...
Top 20 of 90 competitors
NT-112 is an investigational cell therapy being developed by AstraZeneca PLC (ticker AZN) for the treatment of KRAS G12D-mutant solid tumors, including non-small cell lung cancer. It is an autologous, engineered T cell therapy designed to target the KRAS G12D mutation. NT-112 is currently in Phase 1 clinical development.
NT-112 is being studied for the treatment of non-small cell lung cancer that is unresectable, advanced, or metastatic and carries a KRAS G12D mutation. It is also being evaluated in other KRAS G12D-positive solid tumors, including colorectal carcinoma, pancreatic ductal adenocarcinoma, and endometrial cancer. NT-112 is investigational and has not been approved for any indication.
NT-112 targets the KRAS G12D mutation. It is an autologous, engineered T cell therapy, meaning a patient's own T cells are modified to recognize and attack cancer cells expressing this specific mutation. The KRAS G12D mutation is a driver alteration found in several solid tumor types, including non-small cell lung cancer.
NT-112 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the ongoing Phase 1 clinical trial evaluating NT-112 in patients with KRAS G12D-mutant solid tumors.
NT-112 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any regulatory authority. The Phase 1 trial is currently recruiting participants.
NT-112 is being evaluated in a Phase 1 clinical trial, NCT06218914, titled "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors." The trial is recruiting and plans to enroll 108 participants in the United States. It includes patients with non-small cell lung cancer, colorectal carcinoma, pancreatic ductal adenocarcinoma, endometrial cancer, and other KRAS G12D-positive solid tumors.